← Leaderboards

Shari Pilon-Thomas

H. Lee Moffitt Cancer Ctr & Res Inst

Google Scholar ↗PubMed ↗ORCID ↗

$5,168,533

Attributed

$9,473,425

Total exposure

6

Grants

3

Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.

Funding over time

peak $1.8M · FY2008–25

$2M$1.5M$1M$500K$0

'08

'09

'10

'11

'12

'13

'14

'15

'16

'17

'18

'19

'20

'21

'22

'23

'24

'25

Funding mix

By agency

NIH$9,473,425 · 6

By mechanism

R01$5,687,597 · 2

U01$2,595,786 · 1

R00$732,060 · 1

R41$244,801 · 1

K99$213,181 · 1

Top collaborators

Most similar at H. Lee Moffitt Cancer Ctr & Res Inst

Same institution · by research overlap

Others in their field

Top investigators on “Immunotherapy”

Douglas S. Hawkins · Children'S Hosp Of Philadelphia$157,653,178
Constance Ann Benson · University Of California, San Diego$150,079,712
Joseph Sparano · Montefiore Medical Center (Bronx, Ny)$111,361,061
Robert H Vonderheide · University Of Pennsylvania$84,159,371
Sharon A Nachman · Johns Hopkins University$74,725,055
Todd A Alonzo · University Of Colorado Denver/Hsc Denver$72,436,447

Research focus

ImmunotherapyT-LymphocyteTumorMalignant NeoplasmsResponseClinical TrialsIn VivoMouse ModelDoseImmuneTumor GrowthCellsScheduleCancer CellCancer PatientNeoplastic CellProtocols DocumentationCancer TherapyImmune Checkpoint InhibitorPropertyImmune SystemMetabolicMelanomaAnti-Tumor Immune Response

Grant awards (22)

Predict radiation-induced shifts in patient-specific tumor immune ecosystem composition to harness immunological consequences of radiotherapy$499,950

U01 · FY2025 · CA

Mathematical Model-Guided Adoptive Immunotherapy in Bladder Cancer$476,037

R01 · FY2025 · CA

Imaging Acidosis and Immune Therapy in PDAC$649,329

R01 · FY2024 · CA · contact PI

Mathematical Model-Guided Adoptive Immunotherapy in Bladder Cancer$452,237

R01 · FY2024 · CA

Imaging Acidosis and Immune Therapy in PDAC$669,832

R01 · FY2023 · CA · contact PI

Mathematical Model-Guided Adoptive Immunotherapy in Bladder Cancer$466,517

R01 · FY2023 · CA

Predict radiation-induced shifts in patient-specific tumor immune ecosystem composition to harness immunological consequences of radiotherapy$379,908

U01 · FY2023 · CA

Predict radiation-induced shifts in patient-specific tumor immune ecosystem composition to harness immunological consequences of radiotherapy$106,143

U01 · FY2023 · CA

Imaging Acidosis and Immune Therapy in PDAC$669,832

R01 · FY2022 · CA · contact PI

Predict radiation-induced shifts in patient-specific tumor immune ecosystem composition to harness immunological consequences of radiotherapy$484,138

U01 · FY2022 · CA

Mathematical Model-Guided Adoptive Immunotherapy in Bladder Cancer$466,514

R01 · FY2022 · CA

Imaging Acidosis and Immune Therapy in PDAC$683,503

R01 · FY2021 · CA · contact PI

Predict radiation-induced shifts in patient-specific tumor immune ecosystem composition to harness immunological consequences of radiotherapy$629,676

U01 · FY2021 · CA

Mathematical Model-Guided Adoptive Immunotherapy in Bladder Cancer$470,293

R01 · FY2021 · CA

Imaging Acidosis and Immune Therapy in PDAC$683,503

R01 · FY2020 · CA

Predict radiation-induced shifts in patient-specific tumor immune ecosystem composition to harness immunological consequences of radiotherapy$495,971

U01 · FY2020 · CA

Targeting CD137L to MC1R-Expressing Melanoma Cells and Tumors.$244,801

R41 · FY2015 · CA

Anti-melanoma Activity of Combined Lymphopenia and Immunotherapy$241,530

R00 · FY2012 · CA · contact PI

Anti-melanoma Activity of Combined Lymphopenia and Immunotherapy$241,530

R00 · FY2011 · CA · contact PI

Anti-melanoma Activity of Combined Lymphopenia and Immunotherapy$249,000

R00 · FY2010 · CA · contact PI

Anti-melanoma Activity of Combined Lymphopenia and Immunotherapy$107,687

K99 · FY2009 · CA · contact PI

Anti-melanoma Activity of Combined Lymphopenia and Immunotherapy$105,494

K99 · FY2008 · CA · contact PI